Clinical Value of Metagenomic Next-Generation Sequencing in Immunocompromised Patients with Sepsis

Background: Sepsis is a serious threat to human life, particularly in immunocompromised patients; hence, early diagnosis and targeted treatment are important. Metagenomic next-generation sequencing (NGS) has significant advan-tages over traditional diagnostic methods. This study investigated the clinical value of NGS for pathogen iden-tification in immunocompromised patients with sepsis.Material/Methods: From July 2020 to September 2021, 90 consecutive patients with sepsis were enrolled in this prospective study. The patients were divided into 2 groups: an immunocompromised group (n=30) and an immunocompetent group (n=60). The pathogens causing sepsis were concurrently identified using NGS and traditional diagnos-tic methods. The pathogen detection rates and the spectrum of pathogens identified were compared accord-ing to the method of detection and between the immunocompromised and immunocompetent groups.Results: Of the 90 patients, 77 (86%) were positive for 1 or more pathogens using NGS, and 50 (56%) were positive us-ing traditional detection methods. The positivity rate of sputum and bronchoalveolar lavage fluid was higher than that of blood samples. Pneumocystis jirovecii and cytomegalovirus infections were more common in the immunocompromised group than in the immunocompetent group.Conclusions: The performance of NGS in identifying pathogens for patients with sepsis is better than that of traditional de-tection methods, especially in immunocompromised patients. Pneumocystis jirovecii and cytomegalovirus in-fections are more common in immunocompromised patients.